CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 36 enrolled
Drug / intervention
SARS-CoV-2 Virus 1x10^1 TCID50 +3 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04865237
NCT04865237N/ACompleted
CompareCT.gov

A Dose Finding Human Experimental Infection Study in Healthy Subjects Using a GMP-produced SARS-COV-2 Wild Type Strain

Imperial College London·interventional·Posted Apr 29, 2021·Updated May 16, 2025

In Brief

A clinical study evaluating SARS-CoV-2 Virus 1x10^1 TCID50, Remdesivir, and 2 other interventions for Covid19 and 4 related conditions. Completed, enrolled 36 participants across 2 sites.

Detailed Summary

This is a dose optimisation study in healthy adults aged 18-30 who will be experimentally inoculated with SARS-CoV-2. The aim is to cause PCR-confirmed upper respiratory infection in the majority of challenged individuals with minimal or no illness, providing data on the course of COVID-19 and the immune response to SARS-CoV-2 infection. This will establish an optimised dose and study design that will then be used to evaluate the efficacy of treatment and vaccine candidates plus level and duration of immune protection in follow-on trials.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCovid19, SARS-CoV Infection, Corona Virus Infection, Coronavirus, COVID-19
CountriesUnited Kingdom
CollaboratorsHvivo, Royal Free Hospital NHS Foundation Trust

Timeline

N/ACompletedFinished
20222023202420252026
First PostedApr 29, 2021
Enrollment StartMar 6, 2021
Primary CompletionJul 11, 2022
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 5.2 years ago

Interventions

SARS-CoV-2 Virus 1x10^1 TCID50biological

SARS-CoV-2, intranasally, (1x10\^1 TCID50)

Remdesivirdrug

VEKLURY™

SARS-CoV-2 Virus 1x10^2 TCID50biological

SARS-CoV-2, intranasally, (1x10\^2 TCID50)

SARS-CoV-2 Virus 1x10^3 TCID50biological

SARS-CoV-2, intranasally, (1x10\^3 TCID50)